{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:42:52Z","timestamp":1760143372651,"version":"build-2065373602"},"reference-count":56,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Global Health Innovative Technology Fund","award":["G2016-106","G2019-208","JP20lm0203135, AMED"],"award-info":[{"award-number":["G2016-106","G2019-208","JP20lm0203135, AMED"]}]},{"name":"Translational Research Network Program","award":["G2016-106","G2019-208","JP20lm0203135, AMED"],"award-info":[{"award-number":["G2016-106","G2019-208","JP20lm0203135, AMED"]}]},{"name":"NPC","award":["G2016-106","G2019-208","JP20lm0203135, AMED"],"award-info":[{"award-number":["G2016-106","G2019-208","JP20lm0203135, AMED"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Information on the dynamics and decline\/persistence of antibody titres is important in vaccine development. A recent vaccine trial in malaria-exposed, healthy African adults and children living in a malaria hyperendemic and seasonal area (Ouagadougou, Burkina Faso) was the first study in which BK-SE36\/CpG was administered to different age groups. In 5- to 10-year-old children, the risk of malaria infection was markedly lower in the BK-SE36\/CpG arm compared to the control arm. We report here data on antibody titres measured in this age-group after the high malaria transmission season of 2021 (three years after the first vaccine dose was administered). At Year 3, 83% of children had detectable anti-SE36 total IgG antibodies. Geometric mean antibody titres and the proportion of children with detectable anti-SE36 antibodies were markedly higher in the BK-SE36\/CpG arm than the control (rabies) arm. The information obtained in this study will guide investigators on future vaccine\/booster schedules for this promising blood-stage malaria vaccine candidate.<\/jats:p>","DOI":"10.3390\/vaccines12020166","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T05:36:43Z","timestamp":1707197803000},"page":"166","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Persistence of Anti-SE36 Antibodies Induced by the Malaria Vaccine Candidate BK-SE36\/CpG in 5\u201310-Year-Old Burkinabe Children Naturally Exposed to Malaria"],"prefix":"10.3390","volume":"12","author":[{"given":"Issa","family":"Nebie","sequence":"first","affiliation":[{"name":"Groupe de Recherche Action en Sant\u00e9 (GRAS), Ouagadougou 10248, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4098-3972","authenticated-orcid":false,"given":"Nirianne Marie Q.","family":"Palacpac","sequence":"additional","affiliation":[{"name":"Department of Malaria Vaccine Development, Research Institute for Microbial Diseases, Osaka University, Suita 565-0871, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith Christiane","family":"Bougouma","sequence":"additional","affiliation":[{"name":"Groupe de Recherche Action en Sant\u00e9 (GRAS), Ouagadougou 10248, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amidou","family":"Diarra","sequence":"additional","affiliation":[{"name":"Groupe de Recherche Action en Sant\u00e9 (GRAS), Ouagadougou 10248, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3520-6637","authenticated-orcid":false,"given":"Alphonse","family":"Ou\u00e9draogo","sequence":"additional","affiliation":[{"name":"Groupe de Recherche Action en Sant\u00e9 (GRAS), Ouagadougou 10248, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"D\u2019Alessio","sequence":"additional","affiliation":[{"name":"European Vaccine Initiative, Universit\u00e4tsKlinikum Heidelberg, Vo\u00dfstra\u00dfe 2, 69115 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Houard","sequence":"additional","affiliation":[{"name":"European Vaccine Initiative, Universit\u00e4tsKlinikum Heidelberg, Vo\u00dfstra\u00dfe 2, 69115 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5104-3946","authenticated-orcid":false,"given":"Alfred B.","family":"Tiono","sequence":"additional","affiliation":[{"name":"Groupe de Recherche Action en Sant\u00e9 (GRAS), Ouagadougou 10248, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Cousens","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Horii","sequence":"additional","affiliation":[{"name":"Department of Malaria Vaccine Development, Research Institute for Microbial Diseases, Osaka University, Suita 565-0871, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0972-4211","authenticated-orcid":false,"given":"Sodiomon B.","family":"Sirima","sequence":"additional","affiliation":[{"name":"Groupe de Recherche Action en Sant\u00e9 (GRAS), Ouagadougou 10248, Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024, January 18). World Malaria Report, Available online: https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2023."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.smim.2018.08.002","article-title":"Correlating efficacy and immunogenicity in malaria vaccine trials","volume":"39","author":"McCall","year":"2018","journal-title":"Semin. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40259-023-00623-4","article-title":"Malaria Vaccines: Progress to Date","volume":"37","author":"Stanisic","year":"2023","journal-title":"BioDrugs"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Takashima, E., Otsuki, H., Morita, M., Ito, D., Nagaoka, H., Yuguchi, T., Hassan, I., and Tsuboi, T. (2024). The need for novel asexual blood-stage malaria vaccine candidates for Plasmodium falciparum. Biomolecules, 14.","DOI":"10.3390\/biom14010100"},{"key":"ref_5","unstructured":"World Health Organization (2024, January 18). Global Technical Strategy for Malaria 2016\u20132030, 2021 Update. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240031357."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s41182-023-00516-w","article-title":"Malaria vaccines: The 60-year journey of hope and final success-lessons learned and future prospects","volume":"51","year":"2023","journal-title":"Trop. Med. Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0140-6736(23)01456-3","article-title":"12 countries to get first doses of malaria vaccine","volume":"402","author":"Devi","year":"2023","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e939357","DOI":"10.12659\/MSM.939357","article-title":"Editorial: Current Status of Two Adjuvanted Malaria Vaccines and the World Health Organization (WHO) Strategy to Eradicate Malaria by 2030","volume":"29","author":"Parums","year":"2023","journal-title":"Med. Sci. Monit."},{"key":"ref_9","unstructured":"World Health Organization (2024, January 19). Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization of 25\u201329 September 2023, Available online: https:\/\/www.who.int\/publications\/m\/item\/highlights-from-the-meeting-of-the-strategic-advisory-group-ofexperts-(sage)-on-immunization25-29-september-2023."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: A randomised controlled trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","article-title":"Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: A phase 1\/2b randomised controlled trial","volume":"22","author":"Datoo","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Datoo, M.S., Dicko, A., Tinto, H., Ou\u00e9draogo, J.-B., Hamaluba, M., Olotu, A., Beaumont, E., Ramos-Lopez, F., Magloire Natama, H., and Weston, S. (2024, January 18). A Phase III Randomised Controlled Trial Evaluating the Malaria Vaccine Candidate R21\/Matrix-M\u2122 in African Children. Available online: https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=4584076.","DOI":"10.2139\/ssrn.4584076"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Tsoumani, M.E., Voyiatzaki, C., and Efstathiou, A. (2023). Malaria vaccines: From the past towards the mRNA vaccine era. Vaccines, 11.","DOI":"10.3390\/vaccines11091452"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(23)00902-9","article-title":"Gavi unveils malaria vaccine plans","volume":"401","author":"Zarocostas","year":"2023","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1021\/acsinfecdis.3c00332","article-title":"Advancements and challenges in developing malaria vaccines: Targeting multiple stages of the parasite life cycle","volume":"9","author":"Rajneesh","year":"2023","journal-title":"ACS Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Calle, C.L., Mordm\u00fcller, B., and Singh, A. (2021). Immunosuppression in malaria: Do Plasmodium falciparum parasites hijack the host?. Pathogens, 10.","DOI":"10.3390\/pathogens10101277"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.celrep.2015.09.004","article-title":"Circulating Th1-cell-type Tfh cells that exhibit impaired B cell help are preferentially activated during acute malaria in children","volume":"13","author":"Portugal","year":"2015","journal-title":"Cell Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ijpara.2021.12.001","article-title":"Age-specific patterns of DBL\u03b1 var diversity can explain why residents of high malaria transmission areas remain susceptible to Plasmodium falciparum blood stage infection throughout life","volume":"52","author":"Tiedje","year":"2022","journal-title":"Int. J. Parasitol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ogutu, B.R., Apollo, O.J., McKinney, D., Okoth, W., Siangla, J., Dubovsky, F., Tucker, K., Waitumbi, J.N., Diggs, C., and Wittes, J. (2009). Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0004708"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4161\/hv.6.8.11446","article-title":"Blood stage vaccines for Plasmodium falciparum: Current status and the way forward","volume":"6","author":"Ellis","year":"2010","journal-title":"Hum. Vaccines"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1016\/j.jmb.2019.05.018","article-title":"Blood-stage malaria parasite antigens: Structure, function, and vaccine potential","volume":"431","author":"Salinas","year":"2019","journal-title":"J. Mol. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1016\/j.vaccine.2021.06.024","article-title":"Extended follow-up of children in a phase2b trial of the GMZ2 malaria vaccine","volume":"39","author":"Dassah","year":"2021","journal-title":"Vaccines"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1590\/s1678-9946202264023","article-title":"Plasmodium falciparum merozoite surface protein 3 as a vaccine candidate: A brief review","volume":"64","author":"Alves","year":"2022","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1093\/infdis\/jit385","article-title":"Plasmodium falciparum merozoite surface antigen, PfRH5, elicits detectable levels of invasion-inhibiting antibodies in humans","volume":"208","author":"Patel","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.medj.2021.03.014","article-title":"Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination","volume":"2","author":"Minassian","year":"2021","journal-title":"Medicine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.medj.2023.07.003","article-title":"Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults","volume":"4","author":"Silk","year":"2023","journal-title":"Medicine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.cell.2007.10.049","article-title":"Subcellular discharge of a serine protease mediates release of invasive malaria parasites from host erythrocytes","volume":"131","author":"Yeoh","year":"2007","journal-title":"Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/mmi.12941","article-title":"Plasmodium falciparum\u2005SERA5 plays a non-enzymatic role in the malarial asexual blood-stage lifecycle","volume":"96","author":"Stallmach","year":"2015","journal-title":"Mol. Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1038\/s41598-018-23194-9","article-title":"Molecular camouflage of Plasmodium falciparum merozoites by binding of host vitronectin to P47 fragment of SERA5","volume":"8","author":"Tougan","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102845","DOI":"10.1016\/j.parint.2023.102845","article-title":"Immune tolerance caused by repeated P. falciparum infection against SE36 malaria vaccine candidate antigen and the resulting limited polymorphism","volume":"99","author":"Palacpac","year":"2024","journal-title":"Parasitol. Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"34363","DOI":"10.1038\/srep34363","article-title":"Antibody titres and boosting after natural malaria infection in BK-SE36 vaccine responders during a follow-up study in Uganda","volume":"6","author":"Yagi","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4161\/hv.22950","article-title":"TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36\/AHG malaria vaccine in nonhuman primate models","volume":"9","author":"Tougan","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"978591","DOI":"10.3389\/fimmu.2022.978591","article-title":"Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children","volume":"13","author":"Bougouma","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7246","DOI":"10.1016\/j.vaccine.2020.09.056","article-title":"First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3)","volume":"38","author":"Ezoe","year":"2020","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.4049\/jimmunol.166.4.2372","article-title":"Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs","volume":"166","author":"Verthelyi","year":"2001","journal-title":"J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.4049\/jimmunol.168.4.1659","article-title":"CpG oligodeoxynucleotides as vaccine adjuvants in primates","volume":"168","author":"Verthelyi","year":"2002","journal-title":"J. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1521-6616(03)00202-X","article-title":"Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates","volume":"109","author":"Verthelyi","year":"2003","journal-title":"Clin. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1267372","DOI":"10.3389\/fimmu.2023.1267372","article-title":"Safety and immunogenicity of BK-SE36\/CpG malaria vaccine in healthy Burkinabe adults and children: A phase 1b randomised, controlled, double-blinded, age de-escalation trial","volume":"14","author":"Bougouma","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_39","unstructured":"Institut National de la Statistique et de la D\u00e9mographie et ICF (2024, February 02). Enqu\u00eate D\u00e9mographique et de Sant\u00e9 du Burkina Faso 2021 (2022). Available online: https:\/\/dhsprogram.com\/pubs\/pdf\/PR139\/PR139.pdf."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"166","DOI":"10.5897\/JPHE2022.1409","article-title":"Seasonal malaria chemoprevention coverage in Burkina Faso in 2018: Descriptive analysis of mothers\u2019 knowledge and attitude during cross sectional survey","volume":"14","author":"Issaka","year":"2022","journal-title":"J. Public Health Epidemiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6862","DOI":"10.1016\/j.vaccine.2009.09.011","article-title":"Safety and immunogenicity of GMZ2\u2014A MSP3-GLURP fusion protein malaria vaccine candidate","volume":"27","author":"Esen","year":"2009","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6698","DOI":"10.1016\/j.vaccine.2010.07.085","article-title":"Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambar\u00e9n\u00e9, Gabon","volume":"28","author":"Szywon","year":"2010","journal-title":"Vaccine"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"B\u00e9lard, S., Issifou, S., Hounkpatin, A.B., Schaumburg, F., Ngoa, U.A., Esen, M., Fendel, R., de Salazar, P.M., M\u00fcrbeth, R.E., and Milligan, P. (2011). A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0022525"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1016\/j.vaccine.2016.07.041","article-title":"A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children","volume":"34","author":"Sirima","year":"2016","journal-title":"Vaccine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12936-018-2280-y","article-title":"Spatio-temporal dynamic of malaria in Ouagadougou, Burkina Faso, 2011\u20132015","volume":"17","author":"Ouedraogo","year":"2018","journal-title":"Malar. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0264-410X(03)00536-X","article-title":"Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children","volume":"22","author":"Genton","year":"2003","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-3024.2006.00901.x","article-title":"Co-infection of helminths and malaria: Modulation of the immune responses to malaria","volume":"28","author":"Hartgers","year":"2006","journal-title":"Parasite Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1475-2875-6-82","article-title":"IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life","volume":"6","author":"Kinyanjui","year":"2007","journal-title":"Malar. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1128\/CMR.00025-08","article-title":"Acquired immunity to malaria","volume":"22","author":"Doolan","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/acel.12326","article-title":"How sex and age affect immune responses, susceptibility to infections, and response to vaccination","volume":"14","author":"Berger","year":"2015","journal-title":"Aging Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1119820","DOI":"10.3389\/fimmu.2023.1119820","article-title":"Plasmodium falciparum infection coinciding with the malaria vaccine candidate BK-SE36 administration interferes with the immune responses in Burkinabe children","volume":"14","author":"Tiono","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/j.vaccine.2010.08.002","article-title":"TLR-based immune adjuvants","volume":"29","author":"Steinhagen","year":"2011","journal-title":"Vaccine"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1038\/s41598-022-05702-0","article-title":"In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy","volume":"12","author":"Okada","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Otsuka, T., Nishida, S., Shibahara, T., Temizoz, B., Hamaguchi, M., Shiroyama, T., Kimura, K., Miyake, K., Hirata, H., and Mizuno, Y. (2022). CpG ODN (K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: A phase I study. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09818-4"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","article-title":"Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: Secondary analysis of data from a phase 3 randomised controlled trial","volume":"15","author":"White","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"eabo6646","DOI":"10.1126\/scitranslmed.abo6646","article-title":"The RTS,S malaria vaccine: Current impact and foundation for the future","volume":"14","author":"Beeson","year":"2022","journal-title":"Sci. Transl. Med."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/2\/166\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:55:46Z","timestamp":1760104546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/2\/166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["vaccines12020166"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12020166","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2024,2,6]]}}}